A late‑stage clinical trial reported a new drug combination that reduced mortality risk by roughly 40% in men with high‑risk biochemically recurrent prostate cancer after prior surgery or radiation. Investigators presented pooled survival and safety data indicating a clinically meaningful survival benefit in a population with limited options. The report did not name all components in the release, but the result signals a potential practice‑changing regimen pending regulatory filings and broader peer‑reviewed publication.